10 July 2015
The theme of the 2015 ASCO (American Society of Clinical Oncology) Conference was: Illumination and Innovation - Transforming Data into Learning
"We are in an information age and there is a lot of data coming at us. We need to become smarter and more nimble about how we look at data and derive knowledge, and then that drives actual decision-making that improves patient outcomes."
- ASCO President Peter Yu, MD
Top 8 highlights from the 2015 ASCO Annual Meeting relevant for patients:
- Earlier chemotherapy may be better
- Neoadjuvant chemotherapy should be considered for localized high-risk prostate cancer patients
- New recommendations for castration-resistant prostate cancer clinical trial design and patient treatment
- New genomic classifier for lethal disease subset
- Stronger and earlier suppression of the androgen receptor may be better:
- Copy number gains or losses may mediate enzalutamide resistance:
- Distinguishing who should receive more therapy:
- A potential benefit for statins
To view the full report click here.
